- Home
- LII vs BIIB Comparison
LII vs BIIB Comparison
Compare LII & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LII
- BIIB
- Stock Information
- Founded
- LII 1895
- BIIB 1978
- Country
- LII United States
- BIIB United States
- Employees
- LII N/A
- BIIB N/A
- Industry
- LII Industrial Machinery/Components
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- LII Industrials
- BIIB Health Care
- Exchange
- LII Nasdaq
- BIIB Nasdaq
- Market Cap
- LII 21.7B
- BIIB 25.1B
- IPO Year
- LII 1999
- BIIB 1991
- Fundamental
- Price
- LII $609.63
- BIIB $159.99
- Analyst Decision
- LII Buy
- BIIB Buy
- Analyst Count
- LII 14
- BIIB 25
- Target Price
- LII $577.08
- BIIB $260.48
- AVG Volume (30 Days)
- LII 281.1K
- BIIB 1.7M
- Earning Date
- LII 10-23-2024
- BIIB 10-30-2024
- Dividend Yield
- LII 0.75%
- BIIB N/A
- EPS Growth
- LII 38.78
- BIIB 10.05
- EPS
- LII 21.04
- BIIB 11.06
- Revenue
- LII $5,151,100,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- LII $5.80
- BIIB N/A
- Revenue Next Year
- LII $7.02
- BIIB N/A
- P/E Ratio
- LII $28.99
- BIIB $14.46
- Revenue Growth
- LII 4.68
- BIIB N/A
- 52 Week Low
- LII $397.34
- BIIB $159.60
- 52 Week High
- LII $653.83
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- LII 49.50
- BIIB 20.34
- Support Level
- LII $614.95
- BIIB $170.71
- Resistance Level
- LII $653.83
- BIIB $175.86
- Average True Range (ATR)
- LII 15.09
- BIIB 5.21
- MACD
- LII -0.46
- BIIB -1.16
- Stochastic Oscillator
- LII 22.48
- BIIB 1.41
About LII Lennox International Inc.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.